» Articles » PMID: 20381870

Progression of Geographic Atrophy and Genotype in Age-related Macular Degeneration

Overview
Journal Ophthalmology
Publisher Elsevier
Specialty Ophthalmology
Date 2010 Apr 13
PMID 20381870
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We sought to determine whether genotype is associated with rate of growth of geographic atrophy (GA) in eyes with age-related macular degeneration (AMD).

Design: Prospective analysis of participants in a randomized controlled clinical trial.

Participants: We included 114 eyes of 114 participants in the Age-Related Eye Disease Study (AREDS).

Methods: Fundus photographs from AREDS participants with GA from whom a DNA specimen had been obtained and serial photographs had been taken over a minimum of 2 years were evaluated for progression as determined by change in cumulative area of GA. All fundus photographs were scanned, digitized, and centrally graded longitudinally for area of GA. The relationship of GA progression with previously identified genetic variants associated with AMD was assessed.

Main Outcome Measures: Genotype frequencies and change in cumulative area of GA.

Results: The mean growth rate of GA for the 114 eyes was 1.79 mm(2)/year (range, 0.17-4.76). No association between growth rate and genotype was present for variants in the CFH, C2, C3, APOE, and TLR3 genes. For the single nucleotide polymorphism rs10490924 in LOC387715/ARMS2, there was a significant association of GA growth rate, both adjusted and unadjusted for initial lesion size, with the homozygous risk genotype as compared with the homozygous nonrisk genotype (unadjusted P = 0.002; Bonferroni-corrected P = 0.014) and for allelic association (Bonferroni-corrected P value = 0.011). Analyses of other measures of GA progression (progression to central GA from extrafoveal GA and development of bilateral GA in those initially with unilateral GA) showed no statistically significant association between progression and the LOC387715/ARMS2/HTRA1 genotype.

Conclusions: Growth rates of GA calculated from digitized serial fundus photographs showed no association with variants in the CFH, C2, C3, APOE, or TLR3 genes. There was a nominally significant association with the LOC387715/ARMS2/HTRA1 genotype, although this finding was not supported by analyses of secondary measures of GA progression. Replication in other populations is needed to establish the existence of an association.

Citing Articles

Long-term macular atrophy growth in neovascular age-related macular degeneration: influential factors and role of genetic variants.

Vofo B, Shwartz Y, Cnaany Y, Jaskoll S, Kramer A, Elbaz-Hayoun S Eye (Lond). 2025; .

PMID: 40065020 DOI: 10.1038/s41433-025-03723-3.


Characterizing Patient Perceptions of Living with Geographic Atrophy: The Global Geographic Atrophy Insights Survey.

Bakri S, Brinkmann C, Mulvey A, Steinberg K, Katz R, Vatsyayan P Clin Ophthalmol. 2024; 18:3725-3737.

PMID: 39691308 PMC: 11651066. DOI: 10.2147/OPTH.S488559.


Toll-Like Receptor Signalling Pathways and the Pathogenesis of Retinal Diseases.

Titi-Lartey O, Mohammed I, Amoaku W Front Ophthalmol (Lausanne). 2024; 2:850394.

PMID: 38983565 PMC: 11182157. DOI: 10.3389/fopht.2022.850394.


Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go.

Csaky K, Miller J, Martin D, Johnson M Am J Ophthalmol. 2024; 263:231-239.

PMID: 38387826 PMC: 11162935. DOI: 10.1016/j.ajo.2024.02.021.


Chemokine Receptor Profile of T Cells and Progression Rate of Geographic Atrophy Secondary to Age-related Macular Degeneration.

Hinnerskov J, Krogh Nielsen M, Thomsen A, Steffensen M, Honore B, Vorum H Invest Ophthalmol Vis Sci. 2024; 65(1):5.

PMID: 38165703 PMC: 10768715. DOI: 10.1167/iovs.65.1.5.


References
1.
Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

2.
Ferris F, Davis M, Clemons T, Lee L, Chew E, Lindblad A . A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol. 2005; 123(11):1570-4. PMC: 1473206. DOI: 10.1001/archopht.123.11.1570. View

3.
Bunce C, Wormald R . Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health. 2006; 6:58. PMC: 1420283. DOI: 10.1186/1471-2458-6-58. View

4.
Luo L, Harmon J, Yang X, Chen H, Patel S, Mineau G . Familial aggregation of age-related macular degeneration in the Utah population. Vision Res. 2008; 48(3):494-500. DOI: 10.1016/j.visres.2007.11.013. View

5.
Schmidt S, Hauser M, Scott W, Postel E, Agarwal A, Gallins P . Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet. 2006; 78(5):852-864. PMC: 1474047. DOI: 10.1086/503822. View